Clinical trial
Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101)
NCT00449202 · Manhattan Pharmaceuticals, Industry · Unknown status
Key facts
| NCT number | NCT00449202 |
|---|---|
| Title | Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101) |
| Official title | A Phase 2a Randomized, Double-Blind, Placebo Controlled, Parallel Group, Safety and Efficacy Study of Two 14 Day Cycles of Oral Doses of Oleoyl-Estrone (MP-101) in Obese Adult Subjects |
| Lead sponsor | Manhattan Pharmaceuticals, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Obesity |
| Intervention type | Drug |
| Interventions | oleoyl-estrone (MP 101) |
| Enrollment | 100 |
| Start date | Jun 1, 2006 |
| First posted | Mar 20, 2007 |
| Last update posted | Mar 20, 2007 |
| Countries | Switzerland, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: